Our Expert Faculty
Rajesh Pahwa, MD, FAAN
Parkinson’s Disease and Movement Disorder Center
University of Kansas Medical Center
Kansas City, KS
Rajesh Pahwa, M.D., is the Laverne and Joyce Rider Professor of Neurology, chief of the Parkinson's and Movement Disorder Division and director of Parkinson Foundation Center of Excellence at the University of Kansas
Rajesh Pahwa, MD, FAAN
Parkinson’s Disease and Movement Disorder Center
University of Kansas Medical Center
Kansas City, KS
Rajesh Pahwa, M.D., is the Laverne and Joyce Rider Professor of Neurology, chief of the Parkinson's and Movement Disorder Division and director of Parkinson Foundation Center of Excellence at the University of Kansas Medical Center.
Dr. Pahwa received his M.B.B.S. (M.D.) degree at Seth G.S. Medical College, University of Bombay, India. He completed an internship in medicine at Baylor College of Medicine followed by a residency in Neurology at Baylor College of Medicine, Houston, Texas. He then completed a one-year fellowship in movement disorders at the University of Kansas Medical Center. Dr. Pahwa joined the faculty of the Department of Neurology as an instructor in 1992.
Dr. Pahwa was named the inaugural recipient of the Laverne and Joyce Rider Professorship in 2005. This professorship is named for the late Joyce Rider, a longtime Kansas City, Mo., resident, and for her mother, Laverne Stapp Rider, who battled Parkinson's disease for many years. Joyce Rider, who died in 2004, bequeathed financial support for the professorship to the University of Kansas Endowment Association.
Dr. Pahwa is a Diplomate of the American Board of Psychiatry and Neurology. Additionally, the Parkinson’s Disease and Movement Disorders Clinic at The University of Kansas Health System is under Dr. Pahwa’s direction and offers diagnostic and treatment services for people with Parkinson's disease and related disorders such as progressive supranuclear palsy and multiple system atrophy as well as tremor disorders, primary essential tremor.
Disclosures
Dr. Pahwa serves as a consultant for Abbott, AbbVie, ACADIA, Acorda, Allevion, Amneal, Artemida, BioVie, CalaHealth, Convatec,Fasikl, Global Kinetics, Inbeeo, Insightec, Jazz, Kyowa, Lundbeck, Merz, Neurocrine, Neuroderm, Ono, PhotoPharmics, Regenxbio, Sage, Sunovion, Supernus, UCB and Wren. He receives research support from Abbott, AbbVie, Alexza, Annovis, Biogen, Bluerock, Bukwang,Cerevel, Global Kinetics, Jazz, Michael J Fox Foundation, Neuroderm,Neuraly, Parkinson’s Foundation, Praxis, Roche, Sage, Scion, Sun Pharma, UCB, and Voyager.
Stuart Isaacson, MD, FAAN
Parkinson’s Disease Center of Boca Raton
Boca Raton, FL
Dr Stuart Isaacson is a clinical associate professor of neurology at the Florida International University Herbert Wertheim College of Medicine in Miami and director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton in Florida. He is als
Stuart Isaacson, MD, FAAN
Parkinson’s Disease Center of Boca Raton
Boca Raton, FL
Dr Stuart Isaacson is a clinical associate professor of neurology at the Florida International University Herbert Wertheim College of Medicine in Miami and director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton in Florida. He is also the medical director of the not-for-profit organization, Parkinson’s Research and Education Foundation in Boca Raton.
Dr Isaacson’s research focus is the development of new treatments for Parkinson’s disease and other movement disorders, including tardive dyskinesia, essential tremor, dystonia, and atypical forms of parkinsonism. He has been involved in numerous clinical trials and served on national and international committees for many drug development programs and trials, as well as for the Parkinson Study Group and the movement disorders section of the American Academy of Neurology. A prolific author and coauthor of abstracts, journal articles, and book chapters, Dr Isaacson lectures frequently and has presented abstracts at national and international scientific meetings and symposia for patients.
Dr Isaacson earned his medical degree from Northwestern University/Feinberg School of Medicine in Chicago, Illinois. He completed an internship at St Luke’s-Roosevelt Hospital in New York, New York, a residency in neurology, and a fellowship in movement disorders from the Icahn School of Medicine at Mount Sinai, also in New York, and a fellowship at the National Institutes of Health.
Disclosures
Dr. Isaacson receives honoraria for CME, consultant, research grants, and/or promotional speaker on behalf of Abbvie, Acadia, Acorda, Adamas, Addex, Affiris, Alexza, Allergan, Amarantus, Amneal, Aptinyx, Axial, Axovant, Benevolent, Biogen, Biovie, Britannia, Cadent, Cala, Cerecor, Cerevel, Cipla, Eli Lilly, Enterin, GE Healthcare, Global Kinetics, Impax, Impel, Intec Pharma, Ipsen, Jazz, Kyowa Kirin, Lundbeck, Merz, Michael J. Fox Foundation, Mitsubishi Tanabe, Neuralys, Neurocrine, Neuroderm, Novartis, Parkinson Study Group, Pharma2B, Praxis, Prilenia, Promentis, Revance, Roche, Sage, Sanofi, Scion Neurostim, Stoparkinson, Sunovion, Sun Pharma, Supernus, Teva, Theravance, Transposon, UCB
Daniel Kremens, MD, JD, FAAN
Parkinson's Disease and Movement Disorders Center
Thomas Jefferson University
Philadelphia, Pennsylvania
Dr. Kremens is an Associate Professor of Neurology, Co-Director of the Parkinsons Disease and Movement Disorders Center, and Vice Chair for Education at Jefferson Medical College of Thomas Jefferson Univers
Daniel Kremens, MD, JD, FAAN
Parkinson's Disease and Movement Disorders Center
Thomas Jefferson University
Philadelphia, Pennsylvania
Dr. Kremens is an Associate Professor of Neurology, Co-Director of the Parkinsons Disease and Movement Disorders Center, and Vice Chair for Education at Jefferson Medical College of Thomas Jefferson University in Philadelphia. Dr. Kremens graduated from Columbia College, summa cum laude, and was elected to Phi Beta Kappa. He next graduated from Columbia Law School and practiced complex corporate litigation law at major law firms in New York City for seven years. Dr. Kremens then returned to medical school and graduated from Jefferson Medical College where he was elected to Alpha Omega Alpha and won the William F. Kellow Prize and The Arthur Krieger Memorial Prize in Neurology. He completed his residency in Neurology followed by a fellowship in Movement Disorders at The Hospital of the University of Pennsylvania.
Dr Kremens is a diplomat of the American Board of Psychiatry and Neurology and a member of the Movement Disorder Society. His academic interests include neuroprotection and Parkinsons disease and non-motor symptoms in Parkinsons disease. He also is actively involved in medical education and serves as the Clerkship Director in the Department of Neurology at Jefferson Medical College.
Disclosures
Dr. Kremens serves as a consultant for Abbott, AbbVie, ACADIA, Acorda, Adamas, Allergan, Amneal, Avion, GE Healthcare, Kyowa Kirin, Lundbeck, Merz, Neurocrine, Sunovion, Supernus, Teva, and UCB. He has received research support from Acorda, Enterin, Revance and Voyager.
Mark F. Lew, MD
Division of Movement Disorders
Keck Hospital of the University of Southern California
Los Angeles, CA
Dr. Lew has an international reputation for the treatment of patients with Parkinson's disease, dystonia, and other movement disorders. He is a board certified neurologist and a fellow of the American Academy of Neurology.
Mark F. Lew, MD
Division of Movement Disorders
Keck Hospital of the University of Southern California
Los Angeles, CA
Dr. Lew has an international reputation for the treatment of patients with Parkinson's disease, dystonia, and other movement disorders. He is a board certified neurologist and a fellow of the American Academy of Neurology. Dr. Lew is the director of the Division of Movement Disorders and serves as the vice chairman of the Department of Neurology. He has lectured extensively in the United States and abroad on clinical research related to new therapies for Parkinson's disease and dystonia. Dr. Lew also collaborates closely with local and national advocacy organizations (e.g., the Hollyrod Foundation and the National Parkinson's Foundation) to increase public awareness and to support research and care.
Disclosures
Dr. Lew is an advisor/consultant for Supernus, Neurocrine, Acorda, and Kyowa. He is a speaker for Neurocrine, Acorda, and Kyowa. He receives research support from Michael J. Fox Foundation, Pharm2B, Sun Pharma, Neuraly, PSG, NIAA, and Jazz.
Jerrold L Vitek, MD, PhD
Chairman of Neurology
University of Minnesota
Minneapolis, MN
Dr. Jerry Vitek is the Head of the Neurology Department, Director of the Neuromodulation Research Program, and Center Director of the University of Minnesota Udall Center of Excellence for Parkinson's Research. He previously served as the Neuromodulation R
Jerrold L Vitek, MD, PhD
Chairman of Neurology
University of Minnesota
Minneapolis, MN
Dr. Jerry Vitek is the Head of the Neurology Department, Director of the Neuromodulation Research Program, and Center Director of the University of Minnesota Udall Center of Excellence for Parkinson's Research. He previously served as the Neuromodulation Research Center Director at the Lerner Research Institute of the Cleveland Clinic Foundation developing functional surgery and deep brain stimulation (DBS) techniques for the treatment of neurological disease. Dr. Vitek has also held faculty positions at Emory University and The Johns Hopkins University, where he assisted in the development of the functional neurosurgery programs and conducted research on the pathophysiology of movement disorders and mechanism(s) underlying the beneficial effects of DBS.He is currently the PI on several NIH-, foundation- and industry-funded grants, which include both non-human primate and human clinical studies on the neurophysiology of movement disorders and neuromodulation mechanisms. Dr. Vitek is also the PI for an industry-sponsored multicenter phase III pivotal clinical trial to investigate the safety and efficacy of a new neuromodulation device for the purposes of an FDA PMA submission. Many of his research projects involve close collaboration with other neurologists, neuroscientists, neurosurgeons, radiologists, and/or biomedical engineers. Much of this work has provided new insight into the neurophysiology of movement disorders and the therapeutic mechanisms of DBS and contributed to improvements in DBS surgery and treatment as well as the application of DBS to other neurological disorders.
Disclosures
Dr. Vitek has received consulting fees from Abbott, Adamas, Boston Scientific, Insightec, LivaNova, Cala Health and Medtronic. He has received research grants from Boston Scientific, Medtronic, NIH, and St Jude Medical and is on the Scientific Advisory Board for Surgical Information Sciences.